Itami

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Itami

Property Description
Active ingredient Diclofenac (as sodium salt)
Form Medicated Plaster (Transdermal Patch)
Pharmacological class Non-steroidal Anti-inflammatory Drug (NSAID)
Route of administration Topical
Origin Synthetic Compound (Phenylacetic Acid Derivative)

What is the Core Composition and Class of Itami?

Itami is a specific pharmaceutical product containing the active component Diclofenac, which is classified as a Non-steroidal Anti-inflammatory Drug (NSAID). Diclofenac is a synthetic compound derived from the phenylacetic acid family. As an NSAID, its primary function is recognized for its ability to act as a cyclooxygenase (COX) inhibitor. This mechanism reduces the body's synthesis of prostaglandins, which are essential chemical mediators in the inflammatory response. Diclofenac is widely used for its anti-inflammatory and analgesic properties. This active ingredient offers a dual action, helping ease discomfort while reducing the visible signs of local inflammation.


Itami's Unique Form: The Medicated Patch

The physical form of Itami is a medicated plaster—a thin, flexible transdermal patch—designed for topical administration onto the skin. The product is often marketed as an Over-The-Counter (OTC) option for self-medication. This topical formulation is a key feature, as it prioritizes a high concentration of the active ingredient directly at the affected site. The design of this delivery method is specifically associated with low systemic absorption, which is intended to maximize the localized therapeutic effect while minimizing the potential for side effects linked to broader systemic exposure. This patch technology allows for targeted action right where it is needed. This characteristic is especially useful in managing temporary localized muscle discomfort or inflammation stemming from minor physical strains.


What is the General Therapeutic Purpose?

The general purpose of Itami is to offer localized relief from discomfort and to reduce the swelling associated with inflammatory physical conditions. By combining the established efficacy of the Diclofenac compound with a targeted patch delivery, the product aims to mitigate the physical symptoms that arise from localized inflammation. The resulting combination of analgesic and anti-inflammatory action makes the medicated patch a suitable option for self-medication strategies focused on acute local discomfort.

What side effects are possible with Itami?

Possible Side Effects and Safety Information

The safety profile of the Diclofenac medicated plaster is characterized primarily by adverse reactions occurring at the application site, reflecting its topical route of administration. These effects are organized by regulatory authorities into frequency categories, as detailed below.

Classification Examples of Officially Documented Adverse Reactions
Common Pruritus (itching), rash, erythema (redness), dermatitis, burning sensation, and pain at the application site.
Uncommon to Rare Local or generalized hypersensitivity reactions, application site swelling (oedema), and photosensitivity reaction (skin reaction due to light exposure).
Very Rare Severe skin reactions of the bullous type (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis), angioedema (deep swelling), and asthma.

The possibility of systemic adverse reactions associated with the non-steroidal anti-inflammatory drug (NSAID) class cannot be entirely excluded, even with low systemic absorption. Official safety documents note that effects such as those related to the gastrointestinal, renal, or cardiovascular systems may be of greater concern with use over large skin areas or for prolonged periods.

High-level safety constraints documented in regulatory labeling include the instruction not to apply the plaster to broken skin, open wounds, or injuries. The product is also restricted from use in patients who have experienced asthma, urticaria (hives), or acute rhinitis precipitated by aspirin or other NSAIDs, due to the risk of severe reactions.

This framework ensures that the majority of documented adverse events are categorized as local and application-related, while still acknowledging the rare, severe, or systemic risks associated with the NSAID compound.

Overdose and Emergency Response

Overdose and When to Seek Help

Acute Diclofenac overdose, particularly associated with systemic overexposure, requires immediate attention. Officially documented systemic toxicity may present with various clinical signs, primarily involving the gastrointestinal (GI) and central nervous systems (CNS). Documented GI disturbances include nausea, vomiting, and abdominal pain. CNS effects range from headache, dizziness, and drowsiness to more severe presentations like stupor, loss of consciousness, or convulsions. Tinnitus (ringing in the ears) is also listed as a potential manifestation. Severe outcomes officially described in regulatory documentation include serious complications such as acute renal failure, hepatic dysfunction, and gastrointestinal bleeding. These severe systemic effects classify the overdose as potentially life-threatening.

The official regulatory guidance strictly mandates that immediate medical attention must be sought when an overdose is suspected or if any systemic symptoms of toxicity develop. Regulators confirm that no specific antidote is known for Diclofenac poisoning. Consequently, the clinical management of overdose consists of symptomatic and supportive treatment provided by healthcare professionals. Procedures such as forced diuresis, dialysis, or hemoperfusion are noted as being of limited value due to the drug's high degree of protein binding. Hospital monitoring is required until the patient is stabilized.

Therapeutic Uses of Itami

What Itami Treats: Main Uses and Benefits

H2 — Acute Symptomatic Relief from Musculoskeletal Injury

The medication is commonly used to help manage the symptoms of acute soft-tissue injuries of the arms and legs, such as strains, sprains, and contusions (bruises), typically resulting from blunt trauma. The treatment is applied across domains where short-term symptom management is appropriate, in situations where symptoms appear suddenly and create noticeable physiological strain. The key therapeutic benefit provides support that contributes to easing distress related to localized pain and tenderness during the acute episode.

H2 — Management of Localized Discomfort and Swelling

This section applies to conditions presenting with symptoms related to inflammatory or irritative states. It is relevant for therapeutic areas involving heightened tissue reactions where symptoms cluster into patterns of pain coupled with visible swelling. The patch generally offers supportive symptomatic relief, which may assist with maintaining functional stability and contributes to easing distress and supports patients during episodes of heightened discomfort that create noticeable functional strain and physical discomfort.


Quick Fact: Relief for Localized Pain and Swelling
This topical application is relevant when symptoms are confined to a single area, helping to manage acute, disruptive manifestations of discomfort and physical swelling associated with minor trauma.

Eligibility and Restrictions for Use

Eligibility: Who Can and Cannot Use Itami?

This section summarizes the official population eligibility and non-eligibility for Itami (Diclofenac Medicated Plaster), as defined by governmental regulatory documents. The criteria determine who is approved to use the medicine and who is strictly prohibited.

Absolute Contraindications

The medicine is strictly contraindicated and must not be used by specific patient groups. This includes individuals with a known hypersensitivity to diclofenac or a history of allergic-type reactions, such as asthma or hives, after taking aspirin or any other Non-steroidal Anti-inflammatory Drugs (NSAIDs). It is also contraindicated during the peri-operative period in the setting of Coronary Artery Bypass Graft (CABG) surgery and must not be applied to non-intact or damaged skin.

Age and Physiological Restrictions

The product is approved for use in adults and pediatric patients aged 6 years and older. Safety and efficacy are not established for children younger than 6 years of age.

Pregnancy status imposes strict eligibility rules: the medicine is contraindicated in women at or after 30 weeks gestation (third trimester). Use between 20 and 30 weeks gestation is limited.

Patients with certain underlying conditions, such as advanced renal disease or severe heart failure, are generally advised against use unless directed under specific clinical conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Itami (diclofenac sodium topical plaster) emphasizes the risks associated with the active ingredient, diclofenac, even with topical application. This section describes documented interactions and use restrictions based on government drug labels.

Interaction-Related Restrictions and Warnings

Classification Constraint Contextual Note (Regulatory Basis)
Contraindicated Combinations Do not use in combination with other medicinal products containing diclofenac or other systemic Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Increased risk of systemic adverse reactions and skin reactions.
Allergy/Hypersensitivity Risk Do not use if prior history of asthma attacks, urticaria, or acute rhinitis after taking acetylsalicylic acid (aspirin) or other NSAIDs. Risk of cross-hypersensitivity reactions.
Third Trimester Pregnancy Use is contraindicated. Risk of affecting fetal development, including cardiopulmonary toxicity and renal dysfunction in the fetus.

Population-Specific Interaction Considerations

Population Interaction Concern (Regulatory Basis)
Late Pregnancy Use near the end of pregnancy should be avoided due to the potential for prolongation of bleeding time and inhibition of uterine contractions.
Women Planning Pregnancy Use is not recommended, as the inhibition of prostaglandin synthesis may impair fertility.

This profile is structured to ensure that healthcare providers and users are aware of potential systemic risks, requiring caution despite the topical route of administration.

Mechanism of Action

The active ingredient in Itami, diclofenac sodium, operates by engaging key mechanisms to modulate specific enzyme-driven signaling pathways, influencing signaling dynamics within prostanoid pathways.

Primary Target: Cyclooxygenase (COX) Enzyme Inhibition

The core molecular interaction involves the inhibition of Cyclooxygenase (COX) enzyme activity (COX-1 and COX-2). By blocking these enzymes, the drug modifies early molecular steps that reduce the synthesis rate of downstream pro-inflammatory mediators.

Mechanistic Cascade: Prostanoid Synthesis Diminution

This inhibitory action initiates a molecular cascade resulting in the diminished prostaglandin production. This decrease in prostanoid synthesis, specifically, results in a decrease in excessive local mediator activity, influencing local activity within pathways associated with heightened physiological responses.

System-Level Physiological Consequence: Modulation of Local Mediators

This mechanistic domain outlines the resulting physiological adjustment, which is the targeted modulation of mediator levels within the local microenvironment at the site of application. By modulating activity within key signaling pathways, the mechanism leads to predictable physiological adjustments, influencing the subsequent physiological consequences of the mechanistic cascade.

Dosage and Administration Information

How to Use Itami

This section describes the administration and dosing principles for the Diclofenac medicated plaster.


Administration Protocol

The route of administration for Itami is topical (cutaneous use), delivered through a transdermal patch applied directly to the skin. The medicine is intended for short-term treatment and its duration of use is typically not to exceed 7 days for the self-management of acute minor musculoskeletal injuries. Usage is based on a defined schedule rather than a variable as-needed basis.


Standard Dosing and Frequency

The standard regimen involves applying one medicated plaster to the affected area. This application is carried out twice daily, once in the morning and once in the evening, maintaining an interval of approximately 12 hours between applications. The maximum limit is two plasters applied within any 24-hour period, regardless of the area being treated.


Procedural and Population Constraints

The medicated plaster must be applied only to intact, non-diseased skin and should not be covered with an occlusive dressing. The plaster must be removed prior to bathing or showering. In terms of population, use is specifically for adolescents from 16 years of age. The product is not recommended for use in children and adolescents under 16 years old due to insufficient data. If an application is missed, the subsequent plaster should be applied at the next regularly scheduled time, maintaining the intended interval.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Summary of Key Research Findings

Research has evaluated whether a relationship exists between the drug and motor function in patients with chronic-stage stroke, and also explored findings related to spasticity and daily activity scores.

A large-scale Randomized Controlled Trial (RCT) investigated whether the combination of Drug A and Drug B examined the long-term profile of adverse events and evaluated its relationship with the rate of recurrence.

Studies on Drug A and Drug B Combination

Research explored findings on pain and quality of life related to the combination of Drug A and Drug B, including the time frame of any reported changes.

The study involved 600 participants over a two-year period. Findings varied, with some sub-groups reporting some differences when compared to the control group, while others showed no clear difference compared to the control group.

Evidence on Long-Term Use

The evidence base for the long-term application of Drug A alone remains limited. The most significant data available comes from an open-label, non-controlled extension study involving 50 individuals who were followed for five years.

This extension study examined adverse events during prolonged administration. The study did not evaluate efficacy or provide causal evidence on long-term outcomes.

Patient Guidance on Findings

Findings related to this combination do not constitute clinical guidance. Decisions about treatment, including potential changes or suitability for individuals with moderate symptoms, should be made in consultation with a healthcare professional.

Frequently Asked Questions (FAQ)

Common questions about Itami (FAQ)


Q: Are there special warnings for older adults using Itami?

Official documents state that the plaster should be used with caution in elderly patients. This is because, as a population, they are generally more susceptible to experiencing undesirable effects associated with this class of medicine, even with topical use.

Q: Does Itami have potential interactions with common supplements like Omega-3?

According to the official product information, the systemic absorption of the active ingredient is very low. Due to this low absorption, the risk of developing clinically relevant drug-drug or supplement interactions is generally considered negligible during labeled use of the medicated plaster.

Q: Can I use Itami if I have kidney problems?

Official product information describes the use of the plaster with caution in patients with any degree of impaired renal function (kidney problems). While the risk of systemic effects is low, the possibility cannot be excluded if the product is used over large areas of skin or for a prolonged period.

Q: Is it true that Itami has fewer systemic side effects than oral medicines?

The topical nature of Itami is intended to maximize localized therapeutic effect and minimize exposure elsewhere in the body. Official information notes that the risk of developing systemically induced undesirable effects—such as issues with the stomach, liver, or kidneys—is believed to be low because the systemic absorption of the active ingredient is minimal.

Q: What does it mean if I experience localized redness after using Itami?

Localized redness (erythema) is listed as a common adverse reaction at the application site. Regulatory documents advise that treatment may need to be discontinued immediately if a skin rash develops, as advised in regulatory labeling.

Q: Can Itami be used on open wounds?

Regulatory documents describe restrictions that require the medicated plaster to be applied only to intact, non-diseased skin. It is strictly restricted from use on skin wounds or open injuries.

Q: Is Itami the same as other pain relief medicines I've used?

Itami is a specific product in the class of Non-steroidal Anti-inflammatory Drugs (NSAIDs). It is administered as a topical medicated plaster containing diclofenac, which is designed for localized action, which is a key distinction from oral pain relievers.

Q: Does Itami help with muscle soreness?

The medicine is officially indicated for the topical treatment of acute pain associated with minor strains, sprains, and contusions, which may include muscle discomfort.

Q: How quickly does Itami start working after using it?

Clinical information for the topical patch indicates that localized pain relief is indicated to begin within approximately four hours after the first application.

Q: How long does the effect of Itami typically last?

The patch is designed to deliver the active ingredient over a sustained period. This delivery typically lasts approximately 12 hours, which aligns with the recommended twice-daily application schedule.

Q: Is Itami available over the counter, or do I need a prescription?

The regulatory status of diclofenac medicated patches can vary globally. Some formulations are licensed as prescription-only medicines, while others may be approved for over-the-counter (OTC) use depending on the country's specific licensing and strength.

Q: Is Itami generally used for short-term problems or long-term conditions?

The official product information specifies that the medicine is intended for short-term treatment. Its intended duration of use is short-term for the self-management of acute minor musculoskeletal injuries.

Q: Can Itami cause stomach issues?

While the risk is low, the possibility of systemic adverse events, such as those related to the gastrointestinal system (stomach issues), cannot be entirely excluded. This is a possibility with all NSAID medicines, regardless of low systemic absorption.

Q: What happens if I use Itami with other pain creams or gels?

Regulatory constraints caution against using the plaster in combination with other medicinal products containing diclofenac or other systemic Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), as this may increase the risk of side effects.

Q: Does Itami interact with alcohol?

While systemic absorption is low, official warnings note that concomitant ingestion of alcohol may increase the risk of gastrointestinal mucosal bleeding for medicines in the NSAID class.

Q: Does sun exposure affect how Itami works or cause side effects?

Regulatory documents advise caution regarding exposure to natural or artificial sunlight (solarium radiation) for a time after removal of the medicated plaster. This is to reduce the potential risk of a photosensitisation reaction on the skin.

Q: What is the difference between Itami and a cream that only causes heat?

The active ingredient in Itami, diclofenac, works through a pharmacological action that involves enzyme inhibition to reduce the production of inflammation-causing chemicals. Creams that only cause heat typically work by creating a sensory counter-irritation effect on the skin's surface, rather than directly targeting inflammation.

Q: Can Itami be used for nerve pain?

The product is officially indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions (musculoskeletal injuries). Its use is defined by these approved regulatory indications.

Q: Are there any long-term side effects noted for Itami use?

The official duration of use is short-term. Official documents note that the possibility of systemic adverse events (e.g., cardiovascular or renal effects) may be of greater concern with use over large skin areas or for prolonged periods.

Q: Is Itami safe to use while breastfeeding?

Official information indicates that diclofenac is excreted into breast milk in small amounts. Therefore, the use of the medicated plaster is not recommended during breastfeeding.

Q: What is the typical age range of patients who use Itami?

The product is approved for use in adults and adolescents from 16 years of age. Use is officially not authorized for children and adolescents under 16 years old due to insufficient safety data.

Q: Does Itami interact with antacids or heartburn medicine?

Due to the topical administration, the systemic absorption of the active ingredient is very low. Official documents indicate that the risk of developing clinically relevant drug-drug interactions with oral medicines, such as antacids, is generally considered negligible during labeled use.

Q: Is the research for Itami mainly focused on joint pain or other uses?

Regulatory indications for the product focus on the topical treatment of acute pain due to minor strains, sprains, and contusions. These indications cover common musculoskeletal pain.

Q: Have there been any major studies comparing Itami to placebo?

The approval of any medicinal product's efficacy is based on rigorous data. This typically includes Randomized Controlled Trials (RCTs) that examine the product's effect in comparison to control groups, such as a placebo, to support the authorized indications.

Q: Can I drive or operate machinery after using Itami?

The product's package leaflet indicates that the topical plaster is described as having no or negligible influence on the ability to drive and use machines.

Q: Why is Itami only recommended for certain types of pain?

The medicine is intended for the topical treatment of localized, acute pain because its design as a medicated plaster is specifically intended to deliver the active ingredient directly to the site of application, resulting in low systemic absorption.

Q: Does using Itami affect blood pressure?

The possibility of systemic adverse events from the NSAID class, which includes the new onset or worsening of high blood pressure (hypertension), cannot be entirely excluded when used over large skin areas or for prolonged periods.

How should Itami be stored and disposed of?

How to Store and Dispose of Itami?

Official regulatory guidelines strictly govern the storage and disposal of this diclofenac medicated plaster.

Storing the Plasters

The product must be stored in its original sachet and carton to ensure protection from light and desiccation. It is required to keep the plasters at a temperature not exceeding 30°C and it must not be allowed to freeze. After opening the sachet, the remaining patches should be used within three months, and the sachet must be tightly resealed between uses. All patches must be kept out of the sight and reach of children.

Disposing of the Medicine

To protect the environment, the medicine must not be thrown away via household waste or wastewater. For disposal, used plasters should be folded in half, adhesive-side inwards, and then discarded according to the official instructions provided by a pharmacist and local requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Itami found in:

A-Z Index: